Vivos Therapeutics (NASDAQ:VVOS) Posts Quarterly Earnings Results, Beats Expectations By $0.15 EPS

Vivos Therapeutics (NASDAQ:VVOS) issued its quarterly earnings data on Monday. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.15, Zacks reports. The firm had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $3.89 million. Vivos Therapeutics had a negative net margin of 86.19% and a negative return on equity of 335.04%.

Vivos Therapeutics Price Performance

VVOS stock opened at $2.83 on Tuesday. The company’s 50 day simple moving average is $3.72 and its 200-day simple moving average is $3.61. The firm has a market capitalization of $16.64 million, a PE ratio of -0.50 and a beta of 7.47. Vivos Therapeutics has a 12 month low of $1.91 and a 12 month high of $6.28.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.